tesaglitazar interacts_with insulin
Evidence from:
primary |
all sources
Evidence (4 sources)
The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat.
(2013)
PMID:24285952
cited
Tesaglitazar greatly improved insulin's ability to suppress tissue nonoxidative FFA disposal
confidence: 0.90
The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat.
(2013)
PMID:24285952
cited
Tesaglitazar also augmented insulin's ability to quench systemic FFA availability...
confidence: 0.95
The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat.
(2013)
PMID:24285952
cited
Tesaglitazar treatment ... induced a remarkable amelioration in the defects in insulin mediated suppression of plasma FFA and stimulation of Rd′
confidence: 0.85
The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat.
(2013)
PMID:24285952
cited
Tesaglitazar succeeded in completely normalizing the insulin induced increase in R gly.
confidence: 0.70